Literature DB >> 23385295

Behavioural phenotypes of the mucopolysaccharide disorders: a systematic literature review of cognitive, motor, social, linguistic and behavioural presentation in the MPS disorders.

E M Cross1, D J Hare.   

Abstract

BACKGROUND: The mucopolysaccharide disorders (MPS) are a group of recessively inherited metabolic disorders resulting in progressive physical and cognitive decline.
MATERIALS AND METHODS: MEDLINE, PsycINFO and Embase databases were searched, alongside manual screening, to identify relevant literature. Papers were included in the review if they were published in a peer reviewed journal and conducted empirical research into cognitive, motor, social or linguistic development or behaviour in one or more MPS disorders.
RESULTS: Twenty-five papers were reviewed. Two papers used methodology of a sufficiently high standard to demonstrate a behavioural phenotype; both found sleep disturbance to be part of the phenotype of MPS III. Fearfulness and sleep disturbance were frequently observed in people with MPS I and II. Cognitive and motor impairment and decline, and challenging behaviour were highly prevalent in the severe form of MPS II. Cognitive decline and severe behavioural problems relating to aggression, hyperactivity, orality, unusual affect and temper tantrums were seen in MPS III.
CONCLUSIONS: Sleep disturbance is part of the behavioural phenotype of MPS III, and challenging behaviour is highly prevalent in MPS II and MPS III, therefore the efficacy of behavioural interventions for these populations should be investigated. Further research into the behaviour and adaptive skills of children with MPS III and MPS IV is required.

Entities:  

Mesh:

Year:  2013        PMID: 23385295     DOI: 10.1007/s10545-012-9572-0

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  37 in total

1.  Strengthening behavioral research on genetic mental retardation syndromes.

Authors:  R M Hodapp; E M Dykens
Journal:  Am J Ment Retard       Date:  2001-01

2.  Sleep disturbance in Sanfilippo syndrome: a parental questionnaire study.

Authors:  J Fraser; A A Gason; J E Wraith; M B Delatycki
Journal:  Arch Dis Child       Date:  2005-12       Impact factor: 3.791

3.  Gross motor abilities in children with Hurler syndrome.

Authors:  Stacey C Dusing; Deborah Thorpe; Angela Rosenberg; Vicki Mercer; Maria L Escolar
Journal:  Dev Med Child Neurol       Date:  2006-11       Impact factor: 5.449

4.  Behaviour in mucopolysaccharide disorders.

Authors:  M C Bax; G A Colville
Journal:  Arch Dis Child       Date:  1995-07       Impact factor: 3.791

5.  Clinical variability in Sanfilippo B disease: a report on six patients in two related sibships.

Authors:  J J van de Kamp; J F van Pelt; K O Liem; M A Giesberts; L T Niepoth; C R Staalman
Journal:  Clin Genet       Date:  1976-11       Impact factor: 4.438

6.  Development itself is the key to understanding developmental disorders.

Authors:  A Karmiloff-Smith
Journal:  Trends Cogn Sci       Date:  1998-10-01       Impact factor: 20.229

7.  The natural history of the severe form of Hunter's syndrome: a study based on 52 cases.

Authors:  I D Young; P S Harper
Journal:  Dev Med Child Neurol       Date:  1983-08       Impact factor: 5.449

8.  Clinical and genetic spectrum of Sanfilippo type C (MPS IIIC) disease in The Netherlands.

Authors:  G J G Ruijter; M J Valstar; J M van de Kamp; R M van der Helm; S Durand; O P van Diggelen; R A Wevers; B J Poorthuis; A V Pshezhetsky; F A Wijburg
Journal:  Mol Genet Metab       Date:  2007-11-19       Impact factor: 4.797

Review 9.  Is Sanfilippo type B in your mind when you see adults with mental retardation and behavioral problems?

Authors:  Ute Moog; Ingrid van Mierlo; Henny M J van Schrojenstein Lantman-de Valk; Leo Spaapen; Marian A Maaskant; Leopold M G Curfs
Journal:  Am J Med Genet C Semin Med Genet       Date:  2007-08-15       Impact factor: 3.908

Review 10.  Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy.

Authors:  J Edmond Wraith; Maurizio Scarpa; Michael Beck; Olaf A Bodamer; Linda De Meirleir; Nathalie Guffon; Allan Meldgaard Lund; Gunilla Malm; Ans T Van der Ploeg; Jiri Zeman
Journal:  Eur J Pediatr       Date:  2007-11-23       Impact factor: 3.183

View more
  15 in total

1.  Successful spinal anesthesia in a patient with mucopolysaccharidosis type I under femoral fracture reduction and external fixation.

Authors:  Lan Sun; Jianmin Zhang; Xin Zhao
Journal:  Pediatr Investig       Date:  2019-03-22

2.  A Cure for Sanfilippo Syndrome? A Summary of Current Therapeutic Approaches and their Promise.

Authors:  Yewande Pearse; Michelina Iacovino
Journal:  Med Res Arch       Date:  2020-02-21

3.  Parent Experiences of Sanfilippo Syndrome Impact and Unmet Treatment Needs: A Qualitative Assessment.

Authors:  Katherine Ackerman Porter; Cara O'Neill; Elise Drake; Samantha Parker; Maria L Escolar; Stacey Montgomery; William Moon; Carolyn Worrall; Holly L Peay
Journal:  Neurol Ther       Date:  2020-12-02

4.  From hypertransaminasemia to mucopolysaccharidosis IIIA.

Authors:  Paulina Krawiec; Elżbieta Pac-Kożuchowska; Beata Mełges; Agnieszka Mroczkowska-Juchkiewicz; Stanisław Skomra; Agnieszka Pawłowska-Kamieniak; Katarzyna Kominek
Journal:  Ital J Pediatr       Date:  2014-12-02       Impact factor: 2.638

5.  An investigation of the middle and late behavioural phenotypes of Mucopolysaccharidosis Type-III.

Authors:  Elaine M Cross; Sheena Grant; Simon Jones; Brian W Bigger; James E Wraith; Louise V Mahon; Michelle Lomax; Dougal J Hare
Journal:  J Neurodev Disord       Date:  2014-12-31       Impact factor: 4.025

6.  A selective screening program for the early detection of mucopolysaccharidosis: Results of the FIND project - a 2-year follow-up study.

Authors:  Cristóbal Colón; J Victor Alvarez; Cristina Castaño; Luís G Gutierrez-Solana; Ana M Marquez; María O'Callaghan; Félix Sánchez-Valverde; Carmen Yeste; María-Luz Couce
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

7.  Recommendations on clinical trial design for treatment of Mucopolysaccharidosis Type III.

Authors:  Arunabha Ghosh; Elsa Shapiro; Stewart Rust; Kathleen Delaney; Samantha Parker; Adam J Shaywitz; Adelaida Morte; Gillian Bubb; Maureen Cleary; Tien Bo; Christine Lavery; Brian W Bigger; Simon A Jones
Journal:  Orphanet J Rare Dis       Date:  2017-06-26       Impact factor: 4.123

8.  Identification of age-dependent motor and neuropsychological behavioural abnormalities in a mouse model of Mucopolysaccharidosis Type II.

Authors:  Hélène F E Gleitz; Claire O'Leary; Rebecca J Holley; Brian W Bigger
Journal:  PLoS One       Date:  2017-02-16       Impact factor: 3.240

9.  A longitudinal study of emotional adjustment, quality of life and adaptive function in attenuated MPS II.

Authors:  Elsa G Shapiro; Kyle Rudser; Alia Ahmed; Robert D Steiner; Kathleen A Delaney; Brianna Yund; Kelly King; Alicia Kunin-Batson; Julie Eisengart; Chester B Whitley
Journal:  Mol Genet Metab Rep       Date:  2016-04-01

Review 10.  Neurobehavioral phenotypes of neuronopathic mucopolysaccharidoses.

Authors:  Rita Barone; Alessandra Pellico; Annarita Pittalà; Serena Gasperini
Journal:  Ital J Pediatr       Date:  2018-11-16       Impact factor: 2.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.